The Unregulated World of Peptides: A Legal Minefield for Providers Holt Law FDA to weigh easing limits on unproven peptides favored by RFK Jr. and MAHA supporters PBS News BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved drugs with Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Peptide Reclassification 2026 Amanecia Health